Article citationsMore>>

Casarone, M.R., Belcaro, G., Nicolaides, A.N., Geroulakos, G., Griffin, M., Incandela, L., De Sanctis, M.T., Sabetai, M., Geroulakos, G., Agus, G., Bavera, P., Ippolito, E., Leng, G., Di Renzo, A., Cazaubon, M., Vasdekis, S., Christopoulos, D. and Veller, M. (2002) Real Epidemiology of Varicose Veins and Chronic Venous Disease: The San Valentino Vascular Screening Project. Angiology, 53, 119-130.
https://doi.org/10.1177/000331970205300201

has been cited by the following article:

• TITLE: Double-Blind, Parallel Group Study to Compare the Clinical Effectiveness of Calcium Dobesilate 500 mg BID vs. Calcium Dobesilate LP 1 g OD, in Patients with Chronic Venous Insufficiency of the Lower Limbs

  AUTHORS: Ramón Téllez Méndez, Maria González Yibirin, David Rincón Matute

  KEYWORDS: Chronic Venous Insufficiency (CVI), Calcium Dobesilate, CEAP Classification, Adverse Effects, Treatment Adherence

  JOURNAL NAME: International Journal of Clinical Medicine, Vol.15 No.5, May 30, 2024

  ABSTRACT: Background: Chronic venous insufficiency (CVI) describes a condition that affects the venous system of the lower extremities due to venous hypertension (VH. The prevalence is between 5% - 30%. CVI is associated with older age, smoking, lower extremity trauma, presence of an arteriovenous shunt, and elevated estrogen levels. All patients should be initially treated with conservative management. Venoactive drugs like calcium dobesilate are useful. Objectives: The primary objective compared the clinical improvement in patients with CVI, grades 0 - 3 of the CEAP classification of chronic venous disease, produced by two formulations of calcium dobesilate: calcium dobesilate LP 1 g OD vs calcium dobesilate 500 mg BID, immediate release. The secondary objective assessed the side effects of both formulations. Method: All patients took one tablet and one capsule at 7 am, and one capsule at 7 pm, for 8 weeks. One group received dobesilate 1 g OD and the other group received dobesilate 500 md BID. They were evaluated after 15, 30 and 60 days of treatment, using the symptom evaluation scale. Results: In both groups, there was a significant decrease in the symptom score after 15 days. Four patients in the Dobesilate OD group: had adverse effects, which did not require suspension of treatment. In the BID dobesilate group, there was one therapeutic failure, and one case of gastric discomfort. Conclusions: Prolonged-release Calcium dobesilate 1 g OD is as effective as calcium dobesilate 500 mg BID for the treatment of patients with chronic venous insufficiency.